Table 1. Characteristics of all identified studies.
| first author (ref) | year | country | number (F) | pathological classification | molecular classification | Surgery(%) | method | antibody source | definition of Gil+ positive | expression rate (%) | median follow-up (m) | survival analysis | NOS score | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sandra A. O'Toole | 2011 | Australia | 282 | invasive ductal carcinoma/ ductal carcinoma in situ |
NR | NR | IHC | Santa Cruz | ≥20% | 31% | NR | OS | 7 |
| 2 | Lusheng Xu | 2010 | USA | 171 | infiltrating ductal carcinomas | NR | NR | IHC | Santa Cruz | ＞2% | 32.37% | 93.6 | CSS | 7 |
| 3 | Yumei Diao | 2016 | Sweden | 126 | NR | ERα-positive | NR | NR | NR | NR | NR | NR | DMFS | 6 |
| 4 | Shiwei Liu | 2016 | China | 108 | IBC | HER2-positive | 100% | IHC | Abcam | IRS score≥7 | 39.81% | 32 | EFS、PFS | 9 |
| 5 | Bhuvaneswari Ramaswamy | 2012 | U.S. | 289 | IBC | NR | NR | IHC | Sigma | ≥10% | Epithelial 69%, stromal 49% | 96 | OS、DFS | 9 |
| 6 | Yuan Li | 2012 | China | 262 | IBC | All | 100% | IHC | Santa Cruz | score≥2* | 33.59% | 48.2 | OS、DFS | 7 |
| 7 | Miao He | 2015 | China | 290 | NR | NR | 100% | IHC | Abcam | IRS score≥3 | 54.80% | NR | OS、DFS | 10 |
| 8 | Haishan Zhao | 2016 | China | 266 | Invasive ductal carcinoma/ invasive lobular carcinoma |
NR | 100% | IHC | Abcam | IRS score≥3 | 52.60% | 48-77 | OS、DFS | 8 |
| 9 | Anette ten Haaf | 2009 | Germany | 204 | IBC | NR | 100% | IHC | Santa Cruz | IRS score≥7 | 97% | 78 | OS | 10 |
| 10 | Yinghua Li | 2012 | China | 284 | ductal and lobular cancer | NR | 100 | IHC | Santa Cruz | IRS score≥7 | 83.10% | 62 | RFS | 9 |
| 11 | Soyoung Im | 2013 | Korea | 334 | IBC | All | 100 | IHC | Abcam | IRS score≥4 | 42.20% | 75.1 | NR | 8 |
| 12 | Yajun Tao | 2011 | China | 83 | invasive ductal carcinomas/ invasive lobular carcinomas |
All | NR | IHC | Santa Cruz | NR | NR | NR | NR | 10 |
| 13 | Xin Ge | 2015 | China | 117 | NR | NR | NR | IHC | Santa Cruz | IRS score≥5 | NR | NR | NR | 8 |
NR, not reference; IBC, invasive breast cancers; IHC, immunohistochemistry; IRS, immuno-reactive-score; DFS, disease free survival; OS, overall survival; CSS, cause free survival; EFS, event free survival; RFS, recurrence free survival; DMFS, distant metastasis free survival; NOS, Newcastle-Ottawa scale.
The nuclear staining intensity: 0 and 3 (0 = negative, 1 = weak, 2 = moderate, and 3 = strong), the percentage of nuclear stained cells: 0 and 4 (1 ≤25%, 2 = 26−50 %, 3 = 51−75%, and 4 > 75%). IRS was calculated by multiplication of the two scores
*The expressions of Glil was scored as intensity of staining: 0(no staining), 1 (weak/moderate staining) or 2 (intense staining). Glil nuclear over-expression was identified for intensity cases with staining intensity of 2+.